Nuveen LLC bought a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 22,586 shares of the company's stock, valued at approximately $138,000.
Other institutional investors have also recently bought and sold shares of the company. Orbimed Advisors LLC acquired a new position in shares of Upstream Bio during the fourth quarter worth about $93,603,000. VR Adviser LLC bought a new stake in Upstream Bio in the 4th quarter valued at $37,735,000. Wellington Management Group LLP acquired a new position in shares of Upstream Bio in the fourth quarter valued at $25,632,000. Woodline Partners LP bought a new stake in shares of Upstream Bio during the 4th quarter worth about $8,656,000. Finally, Balyasny Asset Management L.P. bought a new position in Upstream Bio in the 4th quarter valued at about $4,951,000.
Wall Street Analyst Weigh In
Separately, Wall Street Zen raised Upstream Bio from a "sell" rating to a "hold" rating in a research report on Friday, June 6th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $56.50.
Check Out Our Latest Research Report on Upstream Bio
Upstream Bio Price Performance
NASDAQ UPB traded up $0.12 during midday trading on Thursday, hitting $17.92. The company had a trading volume of 305,341 shares, compared to its average volume of 515,080. Upstream Bio, Inc. has a twelve month low of $5.14 and a twelve month high of $29.46. The firm has a 50-day moving average price of $15.38 and a 200-day moving average price of $11.16.
Upstream Bio (NASDAQ:UPB - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.13). Upstream Bio had a negative net margin of 3,836.58% and a negative return on equity of 35.90%. The business had revenue of $0.94 million during the quarter, compared to analyst estimates of $0.32 million. As a group, equities analysts predict that Upstream Bio, Inc. will post -4.3 earnings per share for the current fiscal year.
About Upstream Bio
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Read More
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
